Behind The News - 3 July 2012

MORE than two years after CSL’s Fluvax caused febrile convulsions in children aged under five, the company announced preliminary results of its investigation into the adverse events.

It found its method of manufacture retains more virus components than that of other manufacturers, and the characteristics of the 2010 virus components elicited an excessive immune response in some children, triggering the reactions.

The investigation took time due to the complexity of biological factors involved, CSL said.

Associate Professor Heath Kelly
Epidemiologist, ANU

“I THINK I would be speaking for a lot of people when I say two years and some months is a long time to try to find the underlying issue.

“I know other colleagues of mine think the length of time has been reasonable because it is something they [CSL] hadn’t expected.

“CSL didn&rsquo